



# Quintex Pharma Signs Technical Transfer Agreement with Fabtech Technologies Ltd for Manufacturing Intellectual Property

---

*Quintex Pharma signs a TT agreement with Fabtech technologies for the provision of IP services for Quintex Pharma's manufacturing facility in Ghana.*

DELAWARE, USA, November 27, 2023 /EINPresswire.com/ -- Quintex Pharma, a Delaware based start-up pharmaceutical manufacturing company with its planned production base to be situated in Ghana, is thrilled to announce the signing of a ground breaking Technical Transfer Agreement with Fabtech Technologies Ltd, a renowned global innovator in pharmaceutical manufacturing solutions.

This strategic collaboration marks a significant milestone in Quintex Pharma's mission to enhance healthcare access and quality across West Africa. The Technical Transfer Agreement encompasses the transfer of valuable pharmaceutical manufacturing intellectual property from Fabtech Technologies Ltd to Quintex Pharma, facilitating the expansion of Quintex Pharma's product portfolio and manufacturing capabilities.

Fabtech Technologies Ltd, with its extensive experience and expertise in pharmaceutical manufacturing processes and technologies, will be instrumental in aiding Quintex Pharma's efforts to bolster its production capacities and optimize its manufacturing processes. This transfer of knowledge and technology is expected to strengthen Quintex Pharma's position as a leading provider of high-quality generic medications and contract manufacturing services in the region.

Quintex Pharma is excited about the partnership: "This collaboration with Fabtech Technologies Ltd represents a significant step forward in our journey to provide affordable and effective pharmaceutical products in West Africa. We are confident that the transfer of intellectual property and technical expertise will enable us to develop and manufacture high-quality pharmaceuticals that meet the evolving healthcare needs of our region."

Fozi Al Kailani, the representative of Fabtech Technologies Ltd, shared his enthusiasm for the collaboration: "We are pleased to partner with Quintex Pharma, a company that shares our commitment to innovation, quality, and improving healthcare access. This Technical Transfer Agreement aligns with Fabtech's mission to empower pharmaceutical manufacturers worldwide with cutting-edge technology and know-how."

As Quintex Pharma and Fabtech Technologies Ltd embark on this mutually beneficial partnership, they anticipate that it will lead to innovations in pharmaceutical manufacturing, higher product quality, and increased availability of essential medications in West Africa. Both companies are committed to upholding the highest standards of quality and regulatory compliance throughout this collaboration.

For media inquiries or more information about Quintex Pharma's Technical Transfer Agreement with Fabtech Technologies Ltd, please contact:

Quintex Pharma corporate affairs team:  
[Corp.affairs@quintexpharma.com](mailto:Corp.affairs@quintexpharma.com)

#### About Quintex Pharma:

Quintex Pharma is a Delaware holdCo with pharmaceutical manufacturing based in Akuse, Ghana. Quintex Pharma is dedicated to providing high-quality generic medications and contract manufacturing services to improve healthcare access and quality in West Africa.

#### About Fabtech Technologies Ltd:

Fabtech Technologies Ltd is a global leader in pharmaceutical manufacturing solutions, specializing in cutting-edge technology and expertise for pharmaceutical manufacturers worldwide.

Corporate Affairs  
Quintex Pharma  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/671175383>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.